Back to overview

Neumirna featured on MedWatch: “RNA startup from Copenhagen begins hunting for large capital raising”

With a new CEO in place, Sunstone-backed Neumirna aims to land a three-digit million sum in the first half of 2024.
Development
Written by: The Neumirna team
November 10, 2023
Read the full article here.

Related topics

Development
29.4.2026
Dr. Ferenc Tracik Joins Neumirna as Chief Medical Officer
We are excited to announce the appointment of Dr. Ferenc Tracik as Neumirna’s Chief Medical Officer (CMO).
Read full article
Development
Publication
12.1.2026
Neumirna at AES: new data on NMT.001
At the American Epilepsy Society Annual Meeting, Neumirna presented two posters highlighting the potential of its RNA-based approach for drug-resistant epilepsy.
Read full article
Development
17.9.2025
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
We are excited to announce that Ellen K. Donnelly, Ph.D. has been appointed Chief Executive Officer of Neumirna Therapeutics.
Read full article
Back to overview

Neumirna featured on MedWatch: “RNA startup from Copenhagen begins hunting for large capital raising”

With a new CEO in place, Sunstone-backed Neumirna aims to land a three-digit million sum in the first half of 2024.
Development
Written by: The Neumirna team
November 10, 2023
Read the full article here.

Related topics

Development
29.4.2026
Dr. Ferenc Tracik Joins Neumirna as Chief Medical Officer
We are excited to announce the appointment of Dr. Ferenc Tracik as Neumirna’s Chief Medical Officer (CMO).
Read full article
Development
Publication
12.1.2026
Neumirna at AES: new data on NMT.001
At the American Epilepsy Society Annual Meeting, Neumirna presented two posters highlighting the potential of its RNA-based approach for drug-resistant epilepsy.
Read full article
Development
17.9.2025
Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer
We are excited to announce that Ellen K. Donnelly, Ph.D. has been appointed Chief Executive Officer of Neumirna Therapeutics.
Read full article